The oncology and biotech landscape saw notable progress including the ongoing clinical development of Cartography Biosciences’ colorectal cancer targeted therapies supported by a recent $67 million funding round led by Pfizer Ventures. Memorial Sloan Kettering presented cutting-edge radiation therapy findings at ASTRO 2025, highlighting innovations in oncology care. Concurrently, advances in diagnostics include Bio-Rad’s expansion of distribution for Gencurix’s digital PCR kits supporting mutation detection in various cancers, and Predicta Biosciences’ $23.4 million Series A funding to scale genomics platforms for blood cancers and autoimmune diseases. These developments illustrate the dynamic interplay of therapeutics innovation with diagnostic advancement.